简介:摘要:目的:根据近年来产妇臀位外倒转术的实施情况,结合实践案例分析小剂量舒芬太尼腰麻联合利多卡因连硬膜外麻醉的临床应用情况,判断其对臀位外倒转术成功概率构成的影响。方法:以某医院在2019年到2021年期间收治的80名妇产科病人为例,将他们随机分成两组,每组各40人,其中A组选用2%的利多卡因,B组选用2%的利多卡因和小剂量舒芬太尼。主要研究两组孕妇感觉阻滞的起效时间和达到T8平面的时间、手术期间的麻醉效果等。结果:对比A B两组的实验结果发现,B组感受到的阻滞起效时间和达到T8平面的时间都有所下降,手术期间的麻醉效果得到了明显改善,进一步提高了孕妇在手术期间的舒适度。结论:2%的利多卡因和小剂量舒芬太尼硬膜外,麻醉能进一步改善孕妇臀位外倒转术的成功概率,降低手术期间的疼痛感,且不会对新生儿构成不良影响,因此可以在基层医院中广泛应用。
简介: [摘要 ] 目的 探讨美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的疗效及其对炎性因子的影响。 方法 选取 2018年 1月~ 2020年 1月我院收治的溃疡性结肠炎患者 80例,随机分为两组,每组各 40例,两组患者均予常规对症治疗,同时两组均予美沙拉嗪缓释颗粒,观察组同时加用双歧三联活菌胶囊,治疗后比较两组患者治疗后的临床疗效,以及两组患者治疗前后 TNF-α、 IL-10水平的变化情况及两组患者治疗前后的临床症状积分变化情况。结果 观察组治疗后的总有效率为 95.00%,显著高于对照组的总有效率 70.00%,两组疗效比较差异具有显著性( P<0.05)。治疗后,两组患者的炎性因子 TNF-α、 IL-10水平较治疗前显著降低( P<0.05)。且观察组患者治疗后的 TNF-α、 IL-10水平显著低于对照组( P<0.05)。观察组患者治疗后的临床症状积分为( 2.56±0.85)分,与治疗前及对照组比较,差异有统计学意义( P<0.05)。 结论 美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎疗效确切,且可以抑制炎症反应,值得临床推广和应用。 [关键词 ] 溃疡性结肠炎 ;美沙拉嗪 ;双歧三联活菌 ;炎性因子 [Abstract] Objective To investigate the efficacy of mesalazine combined with Bifid Triple Viable Bacteria in the treatment of ulcerative colitis and its influence on inflammatory factors. method Methods: 80 patients with ulcerative colitis in our hospital from January 2018 to January 2020 were selected and randomly divided into two groups, 40 cases in each group. Both groups were given conventional symptomatic treatment, while the two groups were given mesalazine sustained-release granules. The observation group was also given Bifid Triple Viable capsules. After treatment, the clinical efficacy of the two groups of patients after treatment, as well as TNF - α, IL-10 water before and after treatment, were compared between the two groups The changes of the two groups of patients before and after treatment of clinical symptoms integral changes. Results the total effective rate of the observation group was 95.00%, which was significantly higher than that of the control group (70.00%). There was a significant difference between the two groups (P < 0.05). After treatment, the levels of inflammatory factors TNF - α and IL-10 in the two groups were significantly lower than those before treatment (P < 0.05). The levels of TNF - α and IL-10 in the observation group were significantly lower than those in the control group (P < 0.05). The clinical symptom score of the observation group after treatment was (2.56 ± 0.85), and the difference was statistically significant (P < 0.05). Conclusion mesalazine combined with Bifid Triple Viable Bacteria is effective in the treatment of ulcerative colitis, and can inhibit inflammatory reaction, which is worthy of clinical promotion and application.